Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
LXRX Stock Chart & Stats
$1.39
-$0.12(-12.49%)
At close: 4:00 PM EST
$1.39
-$0.12(-12.49%)
Day’s Range― - ―
52-Week Range$0.28 - $2.08
Previous CloseN/A
Volume2.02M
Average Volume (3M)2.74M
Market Cap
$516.03M
Enterprise Value$266.27M
Total Cash (Recent Filing)$139.01M
Total Debt (Recent Filing)$61.45M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
Oct 30, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding363,398,860
10 Day Avg. Volume3,297,817
30 Day Avg. Volume2,735,746
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue4.56
Enterprise Value/Gross Profit4.61
Enterprise Value/Ebitda-2.42
Forecast
1Y Price Target
$1.94Price Target Upside39.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsThe 10 mg dose of pilavapadin is well-characterized and well-positioned to advance into late-stage clinical development with an optimized Phase 3 protocol.
Financial PositionThe exclusive licensing agreement with Novo Nordisk significantly strengthens Lexicon's financial position, providing a cushion that should allow Lexicon to focus resources on pilavapadin's Ph.3 program in DPNP and the Ph.3 SONATA trial for sotagliflozin in Hypertrophic Cardiomyopathy (HCM).
Therapeutic DevelopmentsPilavapadin is validated as a non-opioid therapeutic candidate for diverse chronic neuropathic pain conditions.
Bears Say
Adverse EventsParticipants in the 20 mg arm were the least adherent, potentially driven by increased adverse events and treatment discontinuations leading to lack of responses.
Clinical Trial ChallengesThe study missed the prespecified primary endpoint of ADPS change from baseline to week 8 due to lack of dose response in the 20 mg arm.
Lexicon Pharmaceuticals News
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $0.28 and its highest was $2.08 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is $516.03M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Oct 30, 2025 which is in 7 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Aug 06, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.075 by $0.085.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.07.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 363,398,860 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.075. Following the earnings report the stock price went up 9.524%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in LXRX
Lexicon Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.94 (39.57% Upside)
$1.94 (39.57% Upside)
Hedge Fund Trend
Decreased
By 229.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.35%
12-Months-Change
Fundamentals
Return on Equity
-65.30%
Trailing 12-Months
Asset Growth
-39.58%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
LXRX Company Deck
LXRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Lexicon Pharmaceuticals was largely positive, marked by significant revenue growth, successful strategic repositioning to an R&D-focused company, and promising advancements in the drug pipeline. However, challenges remain in terms of reduced cash reserves and the dependence on partnerships for future progress.View all LXRX earnings summariesLXRX Stock 12 Month Forecast
Average Price Target
$1.94
▲(39.57% Upside)
Technical Analysis
Ownership Overview
13.05% Insiders
8.46% Mutual Funds
0.02% Other Institutional Investors
75.66% Public Companies and
Individual Investors